Showing 5051-5060 of 8162 results for "".
- Revance: RT002 Achieves 6-Month Duration in Phase 3https://practicaldermatology.com/news/revance-rt002-achieves-6-month-duration-in-phase-3/2457959/Revance Therapeutics’ next-generation neuromodulator DaxibotulinumtoxinA for Injection (RT002) delivered positive top-line results in alleviating moderate-to-severe glabellar lines in two pivotal SAKURA Phase 3 trials with duraction of effect up to 6 months. RT002 appeared ge
- FDA Grants Extended Clearance of the Describe Patch for Tattoo Removalhttps://practicaldermatology.com/news/fda-grants-extended-clearance-of-the-describe-patch-for-tattoo-removal/2457960/Merz North America’s DESCRIBE® PFD Patch is now cleared by the Food and Drug Administration (FDA) for all commonly used lasers for tattoo removal. The new FDA clearance also extends the shelf life of the Patch from two years
- AI in Action: New Machine Learning Technique May Enhance Computer-aided Diagnosis of Melanomahttps://practicaldermatology.com/news/ai-in-action-new-machine-learning-technique-may-enhance-computer-aided-diagnosis-of-melanoma/2457963/Researchers at Florida Atlantic University’s College of Engineering and Computer Science have developed a technique using machine learning – a sub-field of artificial intelligence (AI) – that will enha
- Amgen Launches The Enbrel Mini Single-Dose Prefilled Cartridge With AutoTouch Reusable Autoinjectorhttps://practicaldermatology.com/news/amgen-launches-the-enbrel-mini-single-dose-prefilled-cartridge-with-autotouch-reusable-autoinjector/2457966/Amgen's Enbrel Mini with AutoTouch is now available in the United States. Awarded the Arthritis Foundation Ease of Use Commendation, this new and innovative delivery system provides an additional administration option for appropriate Enbrel patients. T
- Parent-supplied Photos May Allow Pediatric Derms to Make Virtual Diagnoseshttps://practicaldermatology.com/news/parent-supplied-photos-may-allow-pediatric-derms-to-make-virtual-diagnoses/2457968/Parent-supplied photos taken via smartphone cameras can allow pediatric dermatologists to make a diagnosis without an office visit in many cases, new research shows. This finding, which appear in JAMA Dermatology, suggest that direct-to-patient dermatology can accurate
- Psoriasis Severity Linked to Diabetes Riskhttps://practicaldermatology.com/news/psoriasis-severity-linked-to-diabetes-risk/2457970/Psoriasis patients are more likely to develop Type 2 diabetes than their psoriasis-free counterparts, and this risk increases dramatically based on the severity of the disease, according to researchers from the Perelman School of Medicine at the University of
- Ortho Dermatologics Announces Aspire Higher Scholarship Honoreeshttps://practicaldermatology.com/news/ortho-dermatologics-announces-aspire-higher-scholarship-honorees/2457972/Ortho Dermatologics announced the nine recipients of the Aspire Higher Scholarship program, which honors the achievements of applicants or current attendees of an accredited, nonprofit, two- or fou
- Calling all Innovators: J & J Launches Digital Beauty QuickFire Challengehttps://practicaldermatology.com/news/calling-all-innovators-j-j-launches-digital-beauty-quickfire-challenge/2457975/Johnson & Johnson Innovation LLC, in collaboration with Johnson & Johnson Consumer Inc., is launching the Digital Beauty QuickFire Challenge. The challenge will encourage start-up companies to create the most novel, future-forward digital
- DermTech Adds Dr. Harold Rabinovitz to Scientific Advisory Boardhttps://practicaldermatology.com/news/dermtech-adds-harold-rabinovitz-to-scientific-advisory-board/2457982/DermTech, Inc., appointed Harold Rabinovitz, MD to its Scientific Advisory Board. Dr. Rabinovitz is a Board Certified Dermatologist and a voluntary Clinical Professor of Dermatology at University of Miami School of Medicine. He is world-renown for his work in dermoscopy and confocal microscopy.</
- Novan Plans to Complete Development of SB204 Acne Candidate via Third Party Funding and Executionhttps://practicaldermatology.com/news/novan-plans-to-complete-development-of-sb204-acne-candidate-via-third-party-funding-and-execution/2457981/Novan, Inc., has agreed in principle to a business structure that would enable further development and advancement of SB204 for the treatment of acne vulgaris via third party financing and third party execution of one additional Phase 3 pivotal trial that is required before the filing of a New Dr